Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes.

We describe the advances to date in utilizing these biomarkers, as well as novel markers of tumor inflammation, to ascertain which patients are most likely to benefit from ICIs. Ongoing translational work promises to improve the proportion of patients who benefit from these agents.
PMID: 30824587 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - February 28, 2019 Category: Cancer & Oncology Authors: Doroshow DB, Sanmamed MF, Hastings K, Politi K, Rimm DL, Chen L, Melero I, Schalper KA, Herbst RS Tags: Clin Cancer Res Source Type: research